Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2007-04-03
Target enrollment:
Participant gender:
Summary
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being
developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long
duration of action of GSK233705 when administered via inhalation in animal models supports
the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary
disease.